CHAPTER 7.

REFERENCES
7.0 REFERENCES


Cullen E et al. Pharmacokinetics an dose proportionality of extended release metformin following administration of 1000, 1500, 2000 and 2500 mg in healthy volunteers. Biopharmaceutics and drug disposition, 2004; 26: 261-263.


European Pharmacopeia, 6th edition European Directorate for the Quality of Medicines 7 allée Kastner, F-67081, Strasbourg. 2006

Evans JMM et al. Socio-economic status, obesity and prevalence of type 1 and type 2 diabetes mellitus. Diabetic Medicine, 2000; 17: 478-480.


Gibson L. Drug regulators study global treaty to tackle counterfeit drugs. BMJ, 2004; 328: 486.

Glucophage XR US Prescribing Information. US Prescribing Information of Glucophage & Glucophage XR. Prinston (NJ); Bristol-Myers Squibb Company, 2004

Glucophage XR US Prescribing Information. US Prescribing Information of Glucophage & Glucophage XR. Prinston (NJ); Bristol-Myers Squibb Company, 2006

137


New Product Focus, 2004, IMS Health Incorporated, 7 Harewood Avenue, London, UK

Nightingale SL and Morrison JC. Generic drugs and the practicing physician, JAMA, 1987; 258: 1200-1204.


PharmEuropa, 6th edition; 2007


Silverman HM. Bioequivalence and Interchangeability of generic drugs, The Merck Manuals. Chapter 17, Published 2007 accessed online on 20th January 2008 (http://www.merck.com/mmhe/sec02/ch017/ch017b.html)

Singh RB et al. Epidemiologic study of diet and coronary risk factors in relation to central obesity and insulin levels in rural and urban populations of north India. Int J Cardiol 1995; 47: 245-55.


Tahara K et al. Determination of antihyperglycemic biguanides in serum and urine using an ion-pair solid-phase extraction technique followed by HPLC-UV on a pentafluorophenylpropyl column and on an octadecyl column. Biomed Chromatogr. 2006; 20:1200-5.


